Merus N.V. (MRUS), a clinical-stage oncology company, will be presenting updated data on its phase II trial of Petosemtamab monotherapy in previously treated, 2L+, recurrent/metastatic head and neck squamous cell carcinoma at the ESMO Asia Congress tomorrow (Dec.7, 2024).
According to the interim clinical update reported at the AACR Annual Meeting last year, Petosemtamab monotherapy in 2L+ HNSCC demonstrated a 37% response rate among 43 evaluable patients.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com